MX2017013390A - Método para el tratamiento de cáncer pulmonar. - Google Patents
Método para el tratamiento de cáncer pulmonar.Info
- Publication number
- MX2017013390A MX2017013390A MX2017013390A MX2017013390A MX2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A MX 2017013390 A MX2017013390 A MX 2017013390A
- Authority
- MX
- Mexico
- Prior art keywords
- fra
- patient
- expression level
- lung cancer
- methods
- Prior art date
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title abstract 4
- 201000005202 lung cancer Diseases 0.000 title abstract 4
- 208000020816 lung neoplasm Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 102000010451 Folate receptor alpha Human genes 0.000 abstract 10
- 108050001931 Folate receptor alpha Proteins 0.000 abstract 10
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 239000012472 biological sample Substances 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
- 230000004043 responsiveness Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562149184P | 2015-04-17 | 2015-04-17 | |
| PCT/US2016/027497 WO2016168440A1 (en) | 2015-04-17 | 2016-04-14 | Methods for treating lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017013390A true MX2017013390A (es) | 2018-06-13 |
Family
ID=55809240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017013390A MX2017013390A (es) | 2015-04-17 | 2016-04-14 | Método para el tratamiento de cáncer pulmonar. |
Country Status (13)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009521206A (ja) * | 2005-04-22 | 2009-06-04 | モルフォテック、インク． | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
| TW201625301A (zh) * | 2014-06-06 | 2016-07-16 | Kyowa Hakko Kirin Co Ltd | 藉由ｆｏｌｒ１標靶藥及葉酸代謝拮抗劑用於癌症患者之治療方法與醫藥 |
| JP7072571B2 (ja) | 2016-11-23 | 2022-05-20 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗葉酸受容体アルファ抗体およびその使用 |
| MX2020009522A (es) | 2018-03-13 | 2020-10-22 | Phanes Therapeutics Inc | Anticuerpos anti-folato del receptor 1 y usos de los mismos. |
| CA3103369A1 (en) * | 2018-06-18 | 2019-12-26 | Medimmune Limited | Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer |
| CN110221052B (zh) * | 2019-06-17 | 2022-09-23 | 昆山德诺瑞尔生物科技有限公司 | Ppfibp1蛋白在制备肝癌术后预后评估试剂盒中的应用 |
| US20250177550A1 (en) * | 2022-03-11 | 2025-06-05 | Astrazeneca Ab | A scoring method for an anti-fr alpha antibody drug conjugate therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050232919A1 (en) * | 2004-02-12 | 2005-10-20 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| JP2009521206A (ja) * | 2005-04-22 | 2009-06-04 | モルフォテック、インク． | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
| GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
| RU2630608C2 (ru) | 2010-11-05 | 2017-09-11 | Морфотек Инк. | Рецептор фолиевой кислоты альфа в качестве диагностического и прогностического маркера злокачественных опухолей, экспрессирующих рецептор фолиевой кислоты альфа |
| PL2731972T3 (pl) | 2011-07-15 | 2018-06-29 | Eisai R&D Management Co., Ltd. | Przeciwciała skierowane przeciwko receptorowi folianowemu alfa i ich zastosowania |
-
2016
- 2016-04-14 BR BR112017022320A patent/BR112017022320A2/pt not_active Application Discontinuation
- 2016-04-14 SG SG11201708546UA patent/SG11201708546UA/en unknown
- 2016-04-14 CA CA2983126A patent/CA2983126A1/en not_active Abandoned
- 2016-04-14 WO PCT/US2016/027497 patent/WO2016168440A1/en not_active Ceased
- 2016-04-14 US US15/566,888 patent/US20180125970A1/en not_active Abandoned
- 2016-04-14 EP EP16718820.0A patent/EP3283886B1/en active Active
- 2016-04-14 AU AU2016248222A patent/AU2016248222A1/en not_active Abandoned
- 2016-04-14 CN CN201680028727.8A patent/CN107624071A/zh active Pending
- 2016-04-14 JP JP2017554475A patent/JP2018516244A/ja active Pending
- 2016-04-14 RU RU2017136863A patent/RU2718780C9/ru not_active IP Right Cessation
- 2016-04-14 KR KR1020177032864A patent/KR20170137848A/ko not_active Withdrawn
- 2016-04-14 MX MX2017013390A patent/MX2017013390A/es unknown
-
2017
- 2017-10-17 IL IL255079A patent/IL255079A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2718780C9 (ru) | 2020-07-08 |
| EP3283886A1 (en) | 2018-02-21 |
| EP3283886B1 (en) | 2020-01-15 |
| RU2718780C2 (ru) | 2020-04-14 |
| KR20170137848A (ko) | 2017-12-13 |
| AU2016248222A1 (en) | 2017-11-09 |
| CN107624071A (zh) | 2018-01-23 |
| WO2016168440A1 (en) | 2016-10-20 |
| SG11201708546UA (en) | 2017-11-29 |
| JP2018516244A (ja) | 2018-06-21 |
| CA2983126A1 (en) | 2016-10-20 |
| US20180125970A1 (en) | 2018-05-10 |
| IL255079A0 (en) | 2017-12-31 |
| RU2017136863A3 (cg-RX-API-DMAC7.html) | 2019-08-21 |
| BR112017022320A2 (pt) | 2018-07-24 |
| RU2017136863A (ru) | 2019-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017013390A (es) | Método para el tratamiento de cáncer pulmonar. | |
| MX2017014736A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| MX2017014381A (es) | Metodos terapeuticos y diagnosticos para cancer. | |
| JO3681B1 (ar) | استخدام مجموعات الجين الطافر fgfr في الكشف عن مرضى السرطان الذين سوف يستجيبون للعلاج بمثبط fgfr | |
| MX2023001945A (es) | Composiciones y metodos para el cribado de tumores solidos. | |
| EP2209495A4 (en) | TAZ / WWTR1 FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| MX2020001156A (es) | Metodo para el pronostico y tratamiento de metastasis de cancer. | |
| MX2018010361A (es) | Métodos terapéuticos y de diagnóstico para el cáncer. | |
| BR112016018205A8 (pt) | métodos de tratamento de mal de alzheimer, de seleção de pacientes, de identificação de pacientes, de previsão, de otimização da eficácia terapêutica, kit, uso de agente e uso in vitro de agente | |
| MX2018003376A (es) | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. | |
| BR112016007864A2 (pt) | método para a prognose e tratamento de metástase de câncer | |
| MX2018004170A (es) | Biomarcadores relacionados con enfermedades mediadas por interleucina-33 (il-33) y usos de los mismos. | |
| BR112015031729A2 (pt) | sistema de classificação, métodos e kit para classificação, prognóstico e tratamento de câncer de mama | |
| MX2017006242A (es) | Determinacion de niveles de glicosaminoglicanos mediante espectrometria de masas. | |
| MX2018007589A (es) | Ccl20 como indicador de respuesta clinica a antagonistas de il23. | |
| BR112016024143A2 (pt) | tratamento de câncer | |
| WO2015181555A8 (en) | Expression profiling for determining the responsiveness of cancers to treatment with an anti-angiogenic agent | |
| WO2019053116A8 (en) | Method for guidance of fluid therapy based on proadrenomedullin | |
| AR104791A1 (es) | Métodos terapéuticos y diagnósticos para el cáncer | |
| UA95601U (uk) | Спосіб прогнозування зрощення перелому | |
| UA104420U (uk) | Спосіб прогнозування зрощення перелому | |
| UA104421U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95662U (uk) | Спосіб прогнозування зрощення перелому | |
| UA126425U (uk) | Спосіб визначення індивідуального ризику розвитку онкологічної патології у родинах осіб, хворих на рак тіла матки | |
| UA95588U (uk) | Спосіб прогнозування зрощення перелому |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: EISAI INC. |